Meeting Banner
Abstract #4024

In vitro NMR spectroscopy identifies metabolic changes resulting from addition of a novel anti-cancer agent (AZD2014) to standard treatment, guiding potential imaging approaches

Nada Al-Saffar1, Jasmin Sidhu1, Udai Banerji1, Yuen-Li Chung1, and Martin O. Leach1

1The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom

Previous reports showed that activation of the PI3K/mTOR pathway is associated with chemoresistance in ovarian cancer cells, and this can be reversed by combining chemotherapy with the mTORC1/2 inhibitor vistusertib (AZD2014). This combination is now being pursued clinically. In this study, we used NMR spectroscopy to establish biomarkers for this combination in A2780Cis human ovarian carcinoma cells. We report that this combination resulted in decreases in lactate, PC, GPC and tCho and was associated with inhibition of glycolysis- and choline-regulatory enzymes. This indicates that choline metabolites and lactate may provide potential non-invasive biomarkers of tumour response to this combination therapy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here